Drug intelligence / Profile preview

FP011

Development stage: Preclinical
Lead developer: Guangdong Fapon Biopharma
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

FP011 is a trispecific antibody drug candidate developed by Guangdong Fapon Biopharma. It targets three immune checkpoint proteins—CD112R (PVRIG), PD-1 (Programmed cell death protein 1), and TIGIT (T cell immunoglobulin and ITIM domains)—and acts as an antagonist/inhibitor to each. The drug is designed for oncology indications, specifically neoplasms, with the aim of enhancing anti-tumor immune responses by simultaneously blocking multiple inhibitory pathways that suppress T-cell activity in the tumor microenvironment. As of June 2025, FP011 remains in preclinical development[1][9].

Targets

PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)TIGIT (T cell immunoreceptor with Ig and ITIM domains)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on FP011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FP011.

Explore the full profile